1. AstraZeneca, Lilly, Sanofi, and others raise prices to start July — Merck gets a CRL from FDA on Keytruda for hepatocellular carcinoma — 2020 biotech IPOs continue to break records — See more on our front page news Stay updated with the latest pharma-related coronavirus news on our new page
    Dismiss Notice
  2. Please take our quick survey on how COVID-19 is impacting your job It will only take a minute or two to respond. The survey is confidential, and does not require registration. Thank you in advance for your participation. We will provide regular updates on results as responses accumulate.
    Dismiss Notice

So Long Carefusion

Discussion in 'CareFusion' started by Anonymous, Mar 17, 2015 at 9:17 PM.

  1. Anonymous

    Anonymous Guest

    BD acquisition complete. NYSE to delist CFN. Good luck BD.
     
  2. Anonymous

    Anonymous Guest

    Good riddance!
     
  3. Anonymous

    Anonymous Guest

    What about infection prevention?
     
  4. Anonymous

    Anonymous Guest

    They are busy deciding which business to sell. Lost of debt-leveraged on the books. They are going to surgically split the business. JUST WATCH.
     
  5. Anonymous

    Anonymous Guest

    i'm a new employee and i am so curious how this shakes out. internally people seem to believe that all jobs are secure, i knew going into it i was taking a risk. what i didn't know however, wa the mass chaos that exists within this organization. this is not the care fusion i thought it was; this is not the company that appears to be a solid organization. there is no on-boarding process, zero administrative support, and the turn over is incredibly high. even though many people stay within the organization, no one stays in any one job long enough to become an expert in their role or their products. they just move on to something else. it's bizarre. not what i expected.
     
  6. Anonymous

    Anonymous Guest

    The company is a nightmare. You would be smart to focus all of your energy on finding another job
     
  7. Anonymous

    Anonymous Guest

    The interventional specialties group is run by the clueless. They make the mayor of Baltimore look bright. I can only hope BD is run better...but I doubt it. The IS leadership cling to their jobs because they would never survive at a real company.
     
  8. Anonymous

    Anonymous Guest

    i heard that the lowest paid Infusion rep makes $600K - is that possibly true?
     
  9. Anonymous

    Anonymous Guest

    No one makes $600K. IF they did, BD would reduce that to $135K Max.
     
  10. anonymous

    anonymous Guest

    if I may ask what is the average income selling vascular products? thank you in advance for any information you can provide.
     
  11. anonymous

    anonymous Guest

    BD BOUGHT CFN BECAUSE OF INFECTION PREVENTION. They want to get this product global and have the means to do it. Alaris smart pumps and max tech infusion arts all past of BD ability to deliver to patient. The respiratory and vital signs items positioned to be sold as the combined warehouses Ae now in mexicali.
     
  12. anonymous

    anonymous Guest

    Things are different but not terrible.
    We will see how it shakes out. Culture is changing rapidly.
    MPS Surgical will make less $ this year but still decent pay in my mind.
     
  13. anonymous

    anonymous Guest

    Options for Independent Distributors of Carefusion Vertebral Compression Fracture products.
    There are some very good opportunities at Osseon, Dfine and Benvenue for you and your physicians. I know the folks at Osseon and Dfine and would recommend both. I dont know anyone or the products at Benvenue so I cannot comment.